Pyridoxine dipharmacophore derivatives as potent glucokinase activators for the treatment of type 2 diabetes mellitus

[1]  Yongguo Li,et al.  Safety, tolerability, pharmacokinetics, and pharmacodynamics of novel glucokinase activator HMS5552: results from a first-in-human single ascending dose study , 2016, Drug design, development and therapy.

[2]  O. A. Hidalgo,et al.  Implication of Green Tea as a Possible Therapeutic Approach for Parkinson Disease. , 2016, CNS & neurological disorders drug targets.

[3]  S. Mudaliar,et al.  AMG 151 (ARRY‐403), a novel glucokinase activator, decreases fasting and postprandial glycaemia in patients with type 2 diabetes , 2016, Diabetes, obesity & metabolism.

[4]  J. Zhi,et al.  Effects of piragliatin, a glucokinase activator, on fasting and postprandial plasma glucose in patients with type 2 diabetes mellitus , 2016, Journal of clinical pharmacology.

[5]  G. Aliev,et al.  Approaches for the Development of Drugs for Treatment of Obesity and Metabolic Syndrome. , 2016, Current pharmaceutical design.

[6]  R. González-Reyes,et al.  Alterations in Glucose Metabolism on Cognition: A Possible Link Between Diabetes and Dementia. , 2016, Current pharmaceutical design.

[7]  W. S. Denney,et al.  Two dose‐ranging studies with PF‐04937319, a systemic partial activator of glucokinase, as add‐on therapy to metformin in adults with type 2 diabetes , 2015, Diabetes, obesity & metabolism.

[8]  R. Radhakrishnan,et al.  An updated compact review on diabetes and moleculer target of oral hypoglycemic agents , 2014 .

[9]  L. P. Sysoeva,et al.  Synthesis and antibacterial activity of novel phosphonium salts on the basis of pyridoxine. , 2013, Bioorganic & medicinal chemistry.

[10]  S. L. Gwaltney,et al.  Design, synthesis and SAR of novel glucokinase activators. , 2013, Bioorganic & medicinal chemistry letters.

[11]  Y. Terauchi,et al.  [Glucokinase activators]. , 2012, Nihon rinsho. Japanese journal of clinical medicine.

[12]  C. Stanley,et al.  Mutational analysis of allosteric activation and inhibition of glucokinase. , 2011, The Biochemical journal.

[13]  D. Porte,et al.  Glucokinase activators (GKAs) promise a new pharmacotherapy for diabetics , 2010, F1000 medicine reports.

[14]  L. P. Sysoeva,et al.  Theoretical and experimental study on cyclic 6-methyl-2,3,4-tris(hydroxymethyl)pyridin-5-ol acetonides , 2010 .

[15]  Arthur J. Olson,et al.  AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading , 2009, J. Comput. Chem..

[16]  L. P. Sysoeva,et al.  New synthetic method for 2,3,4-tris(hydroxymethyl)- 6-methylpyridin-5-ol , 2009 .

[17]  L. Agius.  Glucokinase and molecular aspects of liver glycogen metabolism. , 2008, The Biochemical journal.

[18]  G. Fisher,et al.  Isolation and culture of skin fibroblasts. , 2005, Methods in molecular medicine.

[19]  J. Grippo,et al.  Allosteric Activators of Glucokinase: Potential Role in Diabetes Therapy , 2003, Science.